At the news
? NEUTRALIMPACT 3/10 6-K filed Apr 23, 2026 at 07:05 ET
Purple Biotech announced the formation of a Scientific Advisory Board (SAB) composed of leading experts in immunotherapy and oncology to guide the development of its CAPTN-3 tri-specific antibody platform. The SAB includes specialists in T-cell and NK cell biology with direct experience in developing approved T-cell engager therapies.
- Purple Biotech established a Scientific Advisory Board (SAB) to support development of its CAPTN-3 tri-specific antibody platform.
- SAB members include Dr. Amir Horowitz (NK cell biology), Dr. Afshin Dowlati (early-phase clinical development in solid tumors), Dr. Alexander Shoushtari (melanoma and T-cell engager development), and Dr. Max S. Topp (early clinical development of blinatumomab).
- The CAPTN-3 platform is in preclinical development and focuses on masked tri-specific antibodies targeting 5T4 (IM1240) and TROP2 (IM1305).
- No financial terms, clinical data, or material agreements were disclosed in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access